Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, has been awarded a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category, the company announced today. The award recognizes the company's use of artificial intelligence in its Nociscan solution for chronic low back pain, a condition that affects approximately 266 million people worldwide and represents a significant healthcare burden.
This recognition follows Aclarion's earlier selection as a 2025 Digital Health Awards at HLTH winner. Together, these awards highlight growing external validation of Aclarion's mission to bring objective, MR spectroscopy-based biomarker analysis into routine clinical decision-making. The company's approach aims to advance a new model of MedTech innovation built on scalable, cloud-based algorithms.
"Receiving recognition from both the Pinnacle Awards and HLTH underscores the accelerating momentum behind our technology," said Brent Ness, CEO of Aclarion. "Chronic low back pain remains one of the most challenging and costly conditions in medicine. Providing physicians with objective biochemical data has the potential to fundamentally improve how discogenic pain is evaluated and treated."
Aclarion's flagship platform, Nociscan, uses MR spectroscopy to identify chemical biomarkers within intervertebral discs. These biomarkers are processed through proprietary algorithms that classify whether a disc's biochemical profile is consistent with a painful or non-painful disc. Physicians use this information alongside imaging, clinical evaluation, and their own expertise to optimize treatment planning for patients with discogenic low back pain.
The company continues to expand adoption of Nociscan among spine specialists seeking more objective tools. Since Nociscan is delivered through a cloud-based analytics platform, it can be rapidly deployed across imaging centers and health systems without requiring new hardware infrastructure. Clinical data demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
Chronic low back pain is a global healthcare problem, and Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. For more information about Aclarion and its latest news, visit the company's newsroom at https://tinyurl.com/aconnewsroom.
